Probiotic disruption of quorum sensing reduces virulence and increases cefoxitin sensitivity in methicillin-resistant Staphylococcus aureus.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
16 03 2023
Historique:
received: 09 11 2022
accepted: 13 03 2023
entrez: 17 3 2023
pubmed: 18 3 2023
medline: 22 3 2023
Statut: epublish

Résumé

Therapies which target quorum sensing (QS) systems that regulate virulence in methicillin-resistant Staphylococcus aureus (MRSA) are a promising alternative to antibiotics. QS systems play a crucial in the regulation of MRSA antibiotic resistance, exotoxin production, antioxidant protection and immune cell evasion, and are therefore attractive therapeutic targets to reduce the virulence of a pathogen. In the present work the the effects of bioactive peptides isolated from two strains of lactic acid bacteria were tested against antibiotic resistance, carotenoid production, resistance to oxidative killing and biofilm structure in two clinical MRSA isolates. The results obtained from fractional-inhibitory concentration assays with bulk and semi-purified bioactive molecules showed a significant synergistic effect increasing cefoxitin mediated killing of MRSA. This was coupled to a six-fold decrease of the major membrane pigment staphyloxanthin, and a 99% increase in susceptibility to oxidative stress mediated killing. Real-time quantitative PCR analysis of the QS-genes agrA and luxS, showed differential expression between MRSA strains, and a significant downregulation of the hemolysin gene hla. Light microscopy and scanning electron microscopy revealed alteration in biofilm formation and clustering behavior. These results demonstrate that bioactive metabolites may be effectively applied in tandem with beta-lactam antibiotics to sensitize MRSA to cefoxitin. Moreover, these results shown that several key QS-controlled virulence mechanisms are diminished by probiotic metabolites.

Identifiants

pubmed: 36928453
doi: 10.1038/s41598-023-31474-2
pii: 10.1038/s41598-023-31474-2
pmc: PMC10020441
doi:

Substances chimiques

Cefoxitin 6OEV9DX57Y
Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4373

Informations de copyright

© 2023. The Author(s).

Références

Clin Microbiol Infect. 2000 Sep;6(9):503-8
pubmed: 11168186
Sci Rep. 2018 Oct 1;8(1):14578
pubmed: 30275455
J Bacteriol. 1996 Oct;178(20):6036-42
pubmed: 8830703
Nat Rev Microbiol. 2019 Mar;17(3):141-155
pubmed: 30683887
J Biotechnol. 2015 May 10;201:2-14
pubmed: 25220028
PLoS One. 2014 Jul 17;9(7):e98634
pubmed: 25033196
Infect Immun. 1991 Dec;59(12):4332-7
pubmed: 1937793
FEMS Microbiol Lett. 2004 Dec 15;241(2):135-41
pubmed: 15598524
Front Microbiol. 2015 Oct 27;6:1174
pubmed: 26579084
Annu Rev Genet. 2009;43:197-222
pubmed: 19686078
Lancet. 2016 Jan 9;387(10014):176-87
pubmed: 26603922
Int J Med Microbiol. 2006 Apr;296(2-3):133-9
pubmed: 16487744
Infect Immun. 2011 May;79(5):1927-35
pubmed: 21402769
J Bacteriol. 2004 Jul;186(13):4085-99
pubmed: 15205410
Antimicrob Agents Chemother. 2011 Feb;55(2):526-31
pubmed: 21115796
Nat Chem Biol. 2011 Jun;7(6):348-50
pubmed: 21516114
Peptides. 2014 May;55:17-22
pubmed: 24531033
J Clin Invest. 2003 Dec;112(11):1620-5
pubmed: 14660735
J Bacteriol. 2005 Mar;187(5):1799-814
pubmed: 15716452
J Bacteriol. 2005 Dec;187(23):8181-4
pubmed: 16291691
Front Pharmacol. 2018 Mar 07;9:203
pubmed: 29563876
Front Microbiol. 2016 Sep 22;7:1460
pubmed: 27713728
Appl Environ Microbiol. 2009 Feb;75(4):1165-72
pubmed: 19088323
PLoS One. 2016 Jul 21;11(7):e0159768
pubmed: 27441894
Cell Host Microbe. 2015 Nov 11;18(5):604-12
pubmed: 26567511
Mol Cell. 2008 Oct 10;32(1):150-8
pubmed: 18851841
Front Microbiol. 2020 May 21;11:1028
pubmed: 32508801
Nature. 2018 Oct;562(7728):532-537
pubmed: 30305736
Trends Microbiol. 2016 Nov;24(11):862-871
pubmed: 27430191
Adv Sci (Weinh). 2019 Mar 30;6(11):1900030
pubmed: 31179216
Annu Rev Microbiol. 2010;64:143-62
pubmed: 20825344
J Bacteriol. 2001 Mar;183(6):1843-52
pubmed: 11222581
J Food Prot. 2010 Mar;73(3):452-60
pubmed: 20202329
Nat Rev Microbiol. 2019 Apr;17(4):203-218
pubmed: 30737488
Int J Food Microbiol. 2009 Apr 30;131(1):30-9
pubmed: 18687499
Antimicrob Agents Chemother. 2000 Feb;44(2):231-8
pubmed: 10639342
Int J Food Microbiol. 2012 Jun 1;156(3):255-63
pubmed: 22541391
J Electron Microsc (Tokyo). 2003;52(4):429-33
pubmed: 14599106
Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9095-100
pubmed: 22586129
J Exp Med. 2005 Jul 18;202(2):209-15
pubmed: 16009720
Antimicrob Agents Chemother. 2015 Mar;59(3):1512-8
pubmed: 25534736
Nat Microbiol. 2019 Jul;4(7):1114-1119
pubmed: 30936487

Auteurs

Monica Angela Cella (MA)

Department of Mechanical Engineering, École de Technologie Supérieure (ÉTS), Montreal, QC, H3C 1K3, Canada.

Thomas Coulson (T)

MicroSintesis Inc., Victoria, PE, COA 2G0, Canada. tcoulson@microsintesis.com.

Samantha MacEachern (S)

MicroSintesis Inc., Victoria, PE, COA 2G0, Canada.

Sara Badr (S)

Department of Mechanical Engineering, École de Technologie Supérieure (ÉTS), Montreal, QC, H3C 1K3, Canada.

Ali Ahmadi (A)

Department of Mechanical Engineering, École de Technologie Supérieure (ÉTS), Montreal, QC, H3C 1K3, Canada.

Mahdis Sadat Tabatabaei (MS)

MicroSintesis Inc., Victoria, PE, COA 2G0, Canada.

Alain Labbe (A)

MicroSintesis Inc., Victoria, PE, COA 2G0, Canada. alabbe@microsintesis.com.

Mansel William Griffiths (MW)

Canadian Research Institute for Food Safety, University of Guelph, Guelph, ON, N1G 2W1, Canada.
Food Science Department, University of Guelph, Guelph, ON, N1G 2W1, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH